Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
  2. News & Events
  3. Press releases
  4. Press releases

Press releases

  • 9 December 2019

    ORYZON presents new efficacy data from its Phase II trial ALICE investigating iadademstat in AML

  • 2 December 2019

    ORYZON to present at upcoming international conferences

  • 11 November 2019

    ORYZON to present at upcoming international conferences

  • 25 October 2019

    ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter, 2019

  • 21 October 2019

    ORYZON updates on new activities

  • 3 October 2019

    ORYZON Presents New Positive REIMAGINE Efficacy Data of Vafidemstat in the Treatment of Aggression

  • 30 September 2019

    ORYZON presents positive efficacy results on iadademstat in ED-SCLC patients at ESMO-2019

  • 23 September 2019

    ORYZON updates on new activities

  • 10 September 2019

    ORYZON presents new positive efficacy data on vafidemstat for treatment of aggression

  • 9 September 2019

    ORYZON’s iadademstat shows efficacy signs in relapsed SCLC

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Next page Next ›
  • Last page Last »

Email alerts

Subscribe and stay up to date with our latest news

Subscribe
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel